Credit Suisse Ag Viridian Therapeutics, Inc.\De Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRDN
# of Institutions
143Shares Held
62.1MCall Options Held
160KPut Options Held
354K-
Paradigm Biocapital Advisors LP New York, NY5.03MShares$61.2 Million3.3% of portfolio
-
State Street Corp Boston, MA4.49MShares$54.6 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$47.2 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.81MShares$46.4 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.66MShares$44.5 Million1.34% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $485M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...